Literature DB >> 27488225

Shifting blame: Buprenorphine prescribers, addiction treatment, and prescription monitoring in middle-class America.

Sonia Mendoza1, Allyssa S Rivera-Cabrero2, Helena Hansen2.   

Abstract

Growing nonmedical prescription opioid analgesic use among suburban and rural Whites has changed the public's perception of the nature of opioid addiction, and of appropriate interventions. Opioid addiction has been recast as a biological disorder in which patients are victims of their neurotransmitters and opioid prescribers are irresponsible purveyors of dangerous substances requiring controls. This framing has led to a different set of policy responses than the "War on Drugs" that has focused on heroin trade in poor urban communities; in response to prescription opioid addiction, prescription drug monitoring programs and tamper-resistant opioid formulations have arisen as primary interventions in place of law enforcement. Through the analysis of preliminary findings from interviews with physicians who are certified to manage opioid addiction with the opioid pharmaceutical buprenorphine, we argue that an increase in prescriber monitoring has shifted the focus from addicted people to prescribers as a threat, paradoxically driving users to illicit markets and constricting their access to pharmaceutical treatment for opioid addiction. Prescriber monitoring is also altering clinical cultures of care, as general physicians respond to heightened surveillance and the psychosocial complexities of treating addiction with either rejection of opioid dependent patients, or with resourceful attempts to create support systems for their treatment where none exists.
© The Author(s) 2016.

Entities:  

Keywords:  buprenorphine; opioid maintenance treatment; prescription monitoring programs

Mesh:

Substances:

Year:  2016        PMID: 27488225      PMCID: PMC5540139          DOI: 10.1177/1363461516660884

Source DB:  PubMed          Journal:  Transcult Psychiatry        ISSN: 1363-4615


  42 in total

1.  Can prescription drug monitoring programs help limit opioid abuse?

Authors:  Hallam M Gugelmann; Jeanmarie Perrone
Journal:  JAMA       Date:  2011-11-23       Impact factor: 56.272

2.  The neuroscience of addiction.

Authors:  Nora Volkow; Ting-Kai Li
Journal:  Nat Neurosci       Date:  2005-11       Impact factor: 24.884

3.  Buprenorphine misuse in Finland.

Authors:  Mauri Aalto; Jukka Halme; Jukka-Pekka Visapää; Mikko Salaspuro
Journal:  Subst Use Misuse       Date:  2007       Impact factor: 2.164

4.  Qualitative research methodologies: ethnography.

Authors:  Scott Reeves; Ayelet Kuper; Brian David Hodges
Journal:  BMJ       Date:  2008-08-07

5.  Uncanny scripts: understanding pharmaceutical emplotment in the aboriginal context.

Authors:  Michael J Oldani
Journal:  Transcult Psychiatry       Date:  2009-03

Review 6.  Opioid dependence treatment, including buprenorphine/naloxone.

Authors:  Dennis W Raisch; Carol L Fye; Kathy D Boardman; Mike R Sather
Journal:  Ann Pharmacother       Date:  2002-02       Impact factor: 3.154

7.  Do prescription monitoring programs impact state trends in opioid abuse/misuse?

Authors:  Liza M Reifler; Danna Droz; J Elise Bailey; Sidney H Schnoll; Reginald Fant; Richard C Dart; Becki Bucher Bartelson
Journal:  Pain Med       Date:  2012-02-02       Impact factor: 3.750

Review 8.  Medication development for addictive disorders: the state of the science.

Authors:  Frank J Vocci; Jane Acri; Ahmed Elkashef
Journal:  Am J Psychiatry       Date:  2005-08       Impact factor: 18.112

9.  The impact of buprenorphine on treatment of opioid dependence in a Medicaid population: recent service utilization trends in the use of buprenorphine and methadone.

Authors:  Bradley D Stein; Adam J Gordon; Mark Sorbero; Andrew W Dick; James Schuster; Carrie Farmer
Journal:  Drug Alcohol Depend       Date:  2011-11-16       Impact factor: 4.492

10.  Rising opioid prescribing in adult U.S. emergency department visits: 2001-2010.

Authors:  Maryann Mazer-Amirshahi; Peter M Mullins; Irit Rasooly; John van den Anker; Jesse M Pines
Journal:  Acad Emerg Med       Date:  2014-03       Impact factor: 3.451

View more
  9 in total

1.  The War on Drugs That Wasn't: Wasted Whiteness, "Dirty Doctors," and Race in Media Coverage of Prescription Opioid Misuse.

Authors:  Julie Netherland; Helena B Hansen
Journal:  Cult Med Psychiatry       Date:  2016-12

2.  Perceptions and preferences for long-acting injectable and implantable medications in comparison to short-acting medications for opioid use disorders.

Authors:  Elizabeth C Saunders; Sarah K Moore; Olivia Walsh; Stephen A Metcalf; Alan J Budney; Emily Scherer; Lisa A Marsch
Journal:  J Subst Abuse Treat       Date:  2020-01-21

3.  A systematic review of patients' and providers' perspectives of medications for treatment of opioid use disorder.

Authors:  Katharine Cioe; Breanne E Biondi; Rebecca Easly; Amanda Simard; Xiao Zheng; Sandra A Springer
Journal:  J Subst Abuse Treat       Date:  2020-09-22

4.  Buprenorphine and methadone treatment for opioid dependence by income, ethnicity and race of neighborhoods in New York City.

Authors:  Helena Hansen; Carole Siegel; Joseph Wanderling; Danae DiRocco
Journal:  Drug Alcohol Depend       Date:  2016-05-04       Impact factor: 4.492

Review 5.  Improving Access to Evidence-Based Medical Treatment for Opioid Use Disorder: Strategies to Address Key Barriers within the Treatment System.

Authors:  Bertha K Madras; N Jia Ahmad; Jenny Wen; Joshua Sharfstein Sharfstein
Journal:  NAM Perspect       Date:  2020-04-27

6.  Policy Pathways to Address Provider Workforce Barriers to Buprenorphine Treatment.

Authors:  Rebecca L Haffajee; Amy S B Bohnert; Pooja A Lagisetty
Journal:  Am J Prev Med       Date:  2018-06       Impact factor: 5.043

Review 7.  Depot Buprenorphine Injection In The Management Of Opioid Use Disorder: From Development To Implementation.

Authors:  Walter Ling; Steve Shoptaw; David Goodman-Meza
Journal:  Subst Abuse Rehabil       Date:  2019-11-29

8.  Survey of Barriers and Facilitators to Prescribing Buprenorphine and Clinician Perceptions on the Drug Addiction Treatment Act of 2000 Waiver.

Authors:  Holly J Lanham; Jennifer Papac; Daniela I Olmos; Emily L Heydemann; Nathalia Simonetti; Susanne Schmidt; Jennifer S Potter
Journal:  JAMA Netw Open       Date:  2022-05-02

9.  Support for evidence-informed opioid policies and interventions: The role of racial attitudes, political affiliation, and opioid stigma.

Authors:  Maria Pyra; Bruce Taylor; Elizabeth Flanagan; Anna Hotton; O'Dell Johnson; Phoebe Lamuda; John Schneider; Harold A Pollack
Journal:  Prev Med       Date:  2022-03-23       Impact factor: 4.637

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.